Contamination found in GLP drugs plants in China (Credits: AI)
\n\nBlack mould on equipment, insect activity and reports of gross contamination at manufacturing facilities supplying weight-loss drug ingredients have raised fresh concerns about the safety of compounded GLP-1 medications. According to a report by international media outlets, citing US Food and Drug Administration (FDA) inspection records obtained through a Freedom of Information Act request, inspectors documented serious deficiencies at two Chinese facilities manufacturing ingredients used in compounded versions of semaglutide and tirzepatide. Both companies were placed on the FDA’s import-alert list, allowing their products to be detained at the US border.
\n\nThe findings raise an important question for people turning to weight-loss injections: can problems with drug manufacturing or formulation put their health at risk?
\n\nGLP-1 medications help regulate blood sugar, appetite and feelings of fullness. Semaglutide is the active ingredient in medicines such as Ozempic and Wegovy, while tirzepatide is used in Mounjaro and Zepbound.
\n\nCompounded medications are customised preparations made by authorised pharmacies or other permitted compounders to meet specific patient needs. However, compounded drugs are not FDA-approved and do not undergo the same premarket review for safety, effectiveness and quality as approved medicines. They are not automatically…
Original source: https://www.timesnownews.com/lifestyle
